|
WO2002090355A1
(en)
|
2001-05-05 |
2002-11-14 |
Smithkline Beecham P.L.C. |
N-aroyl cyclic amines
|
|
GB0115862D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB0124463D0
(en)
|
2001-10-11 |
2001-12-05 |
Smithkline Beecham Plc |
Compounds
|
|
GB0127145D0
(en)
*
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
|
GB0130335D0
(en)
*
|
2001-12-19 |
2002-02-06 |
Smithkline Beecham Plc |
Compounds
|
|
CA2460051A1
(en)
|
2002-07-09 |
2004-01-15 |
Actelion Pharmaceuticals Ltd. |
7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
|
|
DE60309481T2
(de)
*
|
2002-09-18 |
2007-06-21 |
Glaxo Group Ltd., Greenford |
Cyclische n-aroylamine als orexinrezeptorantagonisten
|
|
RU2334735C2
(ru)
|
2002-10-11 |
2008-09-27 |
Актелион Фармасьютиклз Лтд. |
Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина
|
|
GB0225938D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0225944D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ES2297413T3
(es)
|
2003-04-28 |
2008-05-01 |
Actelion Pharmaceuticals Ltd. |
Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina.
|
|
CA2557163C
(en)
|
2004-03-01 |
2011-08-16 |
Idorsia Pharmaceuticals Ltd |
Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
|
|
WO2006081522A2
(en)
*
|
2005-01-26 |
2006-08-03 |
The Regents Of The Unversity Of California |
Modulation of nmda receptor currents via orexin receptor and/or crf receptor
|
|
US7501395B2
(en)
|
2005-04-25 |
2009-03-10 |
Eisai R & D Management Co., Ltd. |
Method of screening for antianxiety drugs
|
|
US20080267888A1
(en)
*
|
2005-05-26 |
2008-10-30 |
Pandey Surendrakumar Satyanara |
Heterocyclic Derivatives
|
|
WO2007136790A2
(en)
*
|
2006-05-18 |
2007-11-29 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
EP2049110B1
(en)
|
2006-07-14 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Bridged diazepan orexin receptor antagonists
|
|
JP2010504957A
(ja)
*
|
2006-09-29 |
2010-02-18 |
アクテリオン ファーマシューティカルズ リミテッド |
３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
|
|
ES2357992T3
(es)
|
2006-12-01 |
2011-05-04 |
Actelion Pharmaceuticals Ltd. |
Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
|
|
PE20081229A1
(es)
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
TW200833328A
(en)
|
2006-12-28 |
2008-08-16 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.1.0]hexane derivatives
|
|
CL2008000836A1
(es)
*
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
JP2010527924A
(ja)
|
2007-05-18 |
2010-08-19 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
|
|
NZ580887A
(en)
|
2007-05-23 |
2012-03-30 |
Merck Sharp & Dohme |
Pyridyl piperidine orexin receptor antagonists
|
|
AU2008260647A1
(en)
|
2007-05-23 |
2008-12-11 |
Merck Sharp & Dohme Corp. |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2371514T3
(es)
*
|
2007-07-03 |
2012-01-04 |
Actelion Pharmaceuticals Ltd. |
Compuestos de 3-aza-biciclo[3.3.0]octano.
|
|
EP2183246A2
(en)
|
2007-07-27 |
2010-05-12 |
Actelion Pharmaceuticals Ltd. |
2-aza-bicyclo-[3.3.0]-octane derivatives
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
JP2010540429A
(ja)
*
|
2007-09-24 |
2010-12-24 |
アクテリオン ファーマシューティカルズ リミテッド |
オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
|
|
ES2385699T3
(es)
|
2008-02-21 |
2012-07-30 |
Actelion Pharmaceuticals Ltd. |
Derivados de 2-aza-biciclo-[2,2,1]heptano
|
|
US20110039857A1
(en)
*
|
2008-04-30 |
2011-02-17 |
Hamed Aissaoui |
Piperidine and pyroolidine compounds
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
WO2010004507A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Actelion Pharmaceuticals Ltd |
Thiazolidine compounds as orexin receptor antagonists
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
AU2009324238A1
(en)
|
2008-12-02 |
2010-06-10 |
Glaxo Group Limited |
N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
EP2421850A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
|
|
JP2013502447A
(ja)
|
2009-08-24 |
2013-01-24 |
グラクソ グループ リミテッド |
睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
|
|
WO2011023585A1
(en)
|
2009-08-24 |
2011-03-03 |
Glaxo Group Limited |
Piperidine derivatives used as orexin antagonists
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
CA2863413A1
(en)
|
2012-02-07 |
2013-08-15 |
Eolas Therapeutics, Inc. |
Substituted prolines / piperidines as orexin receptor antagonists
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
ES2617863T3
(es)
|
2012-06-04 |
2017-06-20 |
Actelion Pharmaceuticals Ltd. |
Derivados de bencimidazol-prolina
|
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
|
EA201500399A1
(ru)
|
2012-10-10 |
2015-09-30 |
Актелион Фармасьютиклз Лтд. |
Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
|
|
KR20150118158A
(ko)
|
2013-02-22 |
2015-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 비시클릭 화합물
|
|
CA2902135A1
(en)
|
2013-03-12 |
2014-09-18 |
Actelion Pharmaceuticals Ltd |
Azetidine amide derivatives as orexin receptor antagonists
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
MY179862A
(en)
|
2013-12-03 |
2020-11-18 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
SI3077391T1
(sl)
|
2013-12-04 |
2018-11-30 |
Idorsia Pharmaceuticals Ltd |
Uporaba benzimidazol-prolinskih derivatov
|
|
UY36272A
(es)
|
2014-08-13 |
2016-02-29 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores de los receptores de orexinas
|
|
AU2017217931B2
(en)
|
2016-02-12 |
2020-10-22 |
Astrazeneca Ab |
Halo-substituted piperidines as orexin receptor modulators
|
|
WO2017194548A1
(en)
|
2016-05-10 |
2017-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
AU2020286381C1
(en)
|
2019-06-04 |
2025-07-10 |
Hager Biosciences, Llc |
Imidazolo derivatives, compositions and methods as orexin antagonists
|
|
AR129309A1
(es)
|
2022-05-13 |
2024-08-07 |
Idorsia Pharmaceuticals Ltd |
Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
|
|
GB202311280D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|
|
GB202311281D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|